Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A. Imel, Anthony A. Portale, Leanne M. Ward et al.|The Lancet|2019Cited by 375
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M. Ward, Erik A. Imel, Francis H. Glorieux et al.|The Journal of Clinical Endocrinology & Metabolism|2022Cited by 78